BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 24151800)

  • 1. Complexities of CYP2D6 gene analysis and interpretation.
    Gaedigk A
    Int Rev Psychiatry; 2013 Oct; 25(5):534-53. PubMed ID: 24151800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication.
    Pułczyńska A; Łukaszkiewicz J; Wojnar M; Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
    Acta Pol Pharm; 2011; 68(1):9-13. PubMed ID: 21485696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
    Ingelman-Sundberg M
    Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
    LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.
    Hicks JK; Swen JJ; Gaedigk A
    Curr Drug Metab; 2014 Feb; 15(2):218-32. PubMed ID: 24524666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
    Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
    J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.
    Haertter S
    Drug Metabol Drug Interact; 2013; 28(4):209-16. PubMed ID: 24088607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
    Neafsey P; Ginsberg G; Hattis D; Sonawane B
    J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.
    Bernard S; Neville KA; Nguyen AT; Flockhart DA
    Oncologist; 2006 Feb; 11(2):126-35. PubMed ID: 16476833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
    Dahl ML
    Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
    Zanger UM; Raimundo S; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of the Important Role of
    Taylor C; Crosby I; Yip V; Maguire P; Pirmohamed M; Turner RM
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33143137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 CYP2D6.
    Wolf CR; Smith G
    IARC Sci Publ; 1999; (148):209-29. PubMed ID: 10493260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population.
    Scordo MG; Dahl ML; Spina E; Cordici F; Arena MG
    Pharmacol Res; 2006 Feb; 53(2):162-5. PubMed ID: 16337409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.